Apoxis SA, a Swiss biopharmaceutical company developing oncology and immunology products, today announced it has acquired exclusive worldwide development and marketing rights for anti-cancer compound FK866 from Astellas Pharma GmbH, Munich, Germany. Apoxis intends to initiate a series of phase II studies of the product, re-named as APO866, in 2006.
